Copyright © 2021 Pharmascimed. All Rights Reserved.
Merck Sharp & Dohme
- Home
- Merck Sharp & Dohme
Beyond Keytruda – What does Merck’s future hold?
- February 7, 2019
- 0
Sales of Merck Sharp & Dohme's immuno-oncology drug Keytruda grew a massive 66% year-on-year bringing in $2.15bn in the fourth quarter surpassing most analysts expectations. Earlier in January MSD announced...
Read moreTrending
Recent Posts
The coming age of biosimilars
- February 26, 2019
- 0
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
AbbVie and Voyager Therapeutics in Parkinson’s Pact
- February 22, 2019
- 0